Volume 11 Issue 1
Jan.  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(1): 19-29
Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Liver Transplantation Group of Branch of Organ Transplantation of Chinese Medical Association. Expert consensus on the management of metabolic diseases in Chinese liver transplant recipients (2019 edition)[J]. ORGAN TRANSPLANTATION, 2020, 11(1): 19-29. doi: 10.3969/j.issn.1674-7445.2020.01.004
Citation: Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Liver Transplantation Group of Branch of Organ Transplantation of Chinese Medical Association. Expert consensus on the management of metabolic diseases in Chinese liver transplant recipients (2019 edition)[J]. ORGAN TRANSPLANTATION, 2020, 11(1): 19-29. doi: 10.3969/j.issn.1674-7445.2020.01.004
shu

Expert consensus on the management of metabolic diseases in Chinese liver transplant recipients (2019 edition)

doi: 10.3969/j.issn.1674-7445.2020.01.004

  • Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of College of Medicine of Zhejiang University, Institute of Organ Transplantation of Zhejiang University, Hangzhou 310003, China

More Information
  • Corresponding author: Xu Xiao, Email:zjxu@zju.edu.cn
  • Received Date: 2019-09-16
    Available Online: 2021-01-19
  • Publish Date: 2020-01-15
    Abstract
  • To further standardize the management of metabolic diseases in liver transplant recipients in China, Expert Consensus on Management of Metabolic Diseases in Liver Transplant Recipients in China (2015 Edition) was revised to Expert Consensus on Management of Metabolic Diseases in Liver Transplant Recipients in China (2019 Edition) by referring to the diagnosis and treatment standards and consensus issued by relevant industry associations at home and abroad in recent years in combination with the clinical diagnosis and treatment experience in liver transplantation in China. The latest edition not only introduces the related contents of diabetes mellitus, hypertension and dyslipidemia, but also supplements relevant contents of hyperuricemia and obesity, aiming to provide more comprehensive guidance on the standardized management of metabolic diseases of liver transplant recipients.

     

    • FullText(HTML)
  • loading
    • References(82)
  • [1]
    中国肝移植注册中心, 国家肝脏移植医疗质量控制中心. 2018中国肝脏移植医疗质量报告[M].中国肝移植注册中心, 2018.
    [2]
    Organ Procurement and Transplantation Network. National Data[EB/OL]. [2019-09-10]. https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/.
    [3]
    JENSSEN T, HARTMANN A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3):172-188. DOI: 10.1038/s41574-018-0137-7.
    [4]
    GOJOWY D, ADAMCZAK M, DUDZICZ S, et al. High frequency of arterial hypertension in patients after liver transplantation[J]. Transplant Proc, 2016, 48(5):1721-1724. DOI: 10.1016/j.transproceed.2015.11.043.
    [5]
    中华医学会器官移植学分会.中国实体器官移植受者血脂管理规范(2019版)[J].器官移植, 2019, 10(2):101-111. DOI: 10.3969/j.issn.1674-7445.2019.02.001.

    Branch of Organ Transplantation of Chinese Medical Association. Management specification for blood lipid on recipients with solid organ transplantation[J]. Organ Transplant, 2019, 10(2):101-111. DOI: 10.3969/j.issn.1674-7445.2019.02.001.
    [6]
    NEAL DA, TOM BD, GIMSON AE, et al. Hyperuricemia, gout, and renal function after liver transplantation[J]. Transplantation, 2001, 72(10):1689-1691. doi: 10.1097/00007890-200111270-00021
    [7]
    LONGENECKER JC, WAHEED S, BANDAK G, et al. Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality[J]. BMC Nephrol, 2017, 18(1):103. DOI: 10.1186/s12882-017-0518-5.
    [8]
    陈池义, 蒋文涛, 张骊, 等.成人肝移植后远期高尿酸血症及肾损害的治疗27例[J].中华器官移植杂志, 2016, 37(7):411-414.DOI:10.3760/cma.j.issn.0254-1785. 2016.07.006.

    CHEN CY, JIANG WT, ZHANG L, et al. Long-term post-liver-transplantation hyperuricemia and treatment of renal function damage: report of 27 adult cases[J]. Chin J Organ Transplant, 2016, 37(7): 411-414. DOI: 10.3760/cma.j.issn.0254-1785.2016.07.006.
    [9]
    饶伟萍, 牛玉坚, 王宏宇, 等.肝移植后高尿酸血症的发生率和相关危险因素分析:单中心回顾性研究[J].中华内分泌外科杂志, 2015, 9(6):493-496. DOI: 10.3760/cma.j.issn.1674-6090.2015.06.014.

    RAO WP, NIU YJ, WANG HY, et al. The incidence and risk factors of hyperuricemia after liver transplantation:a single-center retrospective study[J]. Chin J Endocr Surg, 2015, 9(6):493-496. DOI: 10.3760/cma.j.issn.1674-6090.2015.06.014.
    [10]
    REZENDE ANASTÁCIO L, GARCÍA FERREIRA L, COSTA LIBOREDO J, et al. Overweight, obesity and weight gain up to three years after liver transplantation[J]. Nutr Hosp, 2012, 27(4):1351-1356. DOI: 10.3305/nh.2012. 27.4.5768.
    [11]
    SUNDARAM SS, ALONSO EM, ZEITLER P, et al. Obesity after pediatric liver transplantation: prevalence and risk factors[J]. J Pediatr Gastroenterol Nutr, 2012, 55(6):657-662. DOI: 10.1097/MPG.0b013e318266243c.
    [12]
    DAVIS BC, SHADAB SIDDIQUI M. Liver transplantation: the role of metabolic syndrome[J]. Curr Treat Options Gastroenterol, 2017, 15(2):316-331. DOI: 10.1007/s11938-017-0135-1.
    [13]
    李新宇, 黄磊, 朱继业, 等.肝移植术后生存10年及以上患者远期并发症随访分析[J].中华全科医师杂志, 2019, 18(4):347-351. DOI:10.3760/cma.j.issn.1671-7368. 2019.04.011.

    LI XY, HUANG L, ZHU JY, et al. Complications in patients surviving over ten years after liver transplantation[J]. Chin J Gen Pract, 2019, 18(4):347-351. DOI: 10.3760/cma.j.issn.1671-7368.2019.04.011.
    [14]
    JIMÉNEZ-PÉREZ M, GONZÁLEZ-GRANDE R, OMONTE GUZMÁN E, et al. Metabolic complications in liver transplant recipients[J]. World J Gastroenterol, 2016, 22(28):6416-6423. DOI: 10.3748/wjg.v22.i28.6416.
    [15]
    LUCEY MR, TERRAULT N, OJO L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1):3-26. DOI: 10.1002/lt.23566.
    [16]
    PAREKH J, CORLEY DA, FENG S. Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation[J]. Am J Transplant, 2012, 12(8):2181-2187. DOI: 10.1111/j.1600-6143.2012.04077.x.
    [17]
    李新宇, 朱继业, 黄磊, 等.肝移植术后代谢综合征及危险因素分析[J].中华普通外科杂志, 2012, 27(1):8-11. DOI: 10.3760/cma.j.issn.1007-631X.2012.01.004.

    LI XY, ZHU JY, HUANG L, et al. Metabolic syndrome in liver transplant recipients: prevalence and risk factors[J]. Chin J Gen Surg, 2012, 27(1):8-11. DOI: 10.3760/cma.j.issn.1007-631X.2012.01.004.
    [18]
    KIM WR, LAKE JR, SMITH JM, et al. OPTN/SRTR 2017 annual data report: liver[J]. Am J Transplant, 2019, 19(Suppl 2):184-283. DOI: 10.1111/ajt.15276.
    [19]
    WATT KD, CHARLTON MR. Metabolic syndrome and liver transplantation: a review and guide to management[J]. J Hepatol, 2010, 53(1):199-206. DOI: 10.1016/j.jhep.2010.01.040.
    [20]
    LAISH I, BRAUN M, MOR E, et al. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events[J]. Liver Transpl, 2011, 17(1):15-22. DOI: 10.1002/lt.22198.
    [21]
    DE SIMONE P, CARRAI P, COLETTI L, et al. Everolimus vs mycophenolate mofetil in combination with tacrolimus: a propensity score-matched analysis in liver transplantation[J]. Transplant Proc, 2018, 50(10):3615-3620. DOI: 10.1016/j.transproceed.2018.07.011.
    [22]
    Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9 (Suppl 3): S1-S155. DOI: 10.1111/j.1600-6143.2009.02834.x.
    [23]
    NEUBERGER JM, BECHSTEIN WO, KUYPERS DR, et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) group[J]. Transplantation, 2017, 101(4S Suppl 2): S1-S56. DOI: 10.1097/TP.0000000000001651.
    [24]
    American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019[J]. Diabetes Care, 2019, 42(Suppl 1): S13-S28. DOI: 10.2337/dc19-S002.
    [25]
    American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018[J]. Diabetes Care, 2018, 41(Suppl 1): S13-S27. DOI: 10.2337/dc18-S002.
    [26]
    CHARLTON M, LEVITSKY J, AQEL B, et al. International Liver Transplantation Society consensus statement on immunosuppression in liver transplant recipients[J]. Transplantation, 2018, 102(5):727-743. DOI: 10.1097/TP.0000000000002147.
    [27]
    中国医师协会器官移植医师分会, 中华医学会外科学分会器官移植学组, 中华医学会器官移植学分会肝移植学组.中国肝移植受者代谢病管理专家共识(2015版)[J/CD].中华移植杂志(电子版), 2015, 9(3):103-107. doi: 10.3877/cma.j.issn.1674-3903.2015.03.001

    Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Organ Transplantation Group of Surgery Branch of Chinese Medical Association, Liver Transplantation Group of Branch of Organ Transplantation of Chinese Medical Association. Expert consensus on management of metabolic diseases in Chinese liver transplant recipients (2015 edition) [J/CD]. Chin J Transplant(Electr Vers), 2015, 9(3):103-107. doi: 10.3877/cma.j.issn.1674-3903.2015.03.001
    [28]
    GRANCINI V, RESI V, PALMIERI E, et al. Management of diabetes mellitus in patients undergoing liver transplantation[J]. Pharmacol Res, 2019, 141:556-573. DOI: 10.1016/j.phrs.2019.01.042.
    [29]
    SONG JL, LI M, YAN LN, et al. Higher tacrolimus blood concentration is related to increased risk of post-transplantation diabetes mellitus after living donor liver transplantation[J]. Int J Surg, 2018, 51:17-23. DOI: 10.1016/j.ijsu.2017.12.037.
    [30]
    LI DW, LU TF, HUA XW, et al. Risk factors for new onset diabetes mellitus after liver transplantation: a Meta-analysis[J]. World J Gastroenterol, 2015, 21(20):6329-6340. DOI: 10.3748/wjg.v21.i20.6329.
    [31]
    YAGI S, KAIDO T, IIDA T, et al. New-onset diabetes mellitus after living-donor liver transplantation: association with graft synthetic function[J]. Surg Today, 2017, 47(6):733-742. DOI: 10.1007/s00595-016-1444-z.
    [32]
    CEN C, FANG HX, YU SF, et al. Association between ADIPOQ gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(6):602-609. DOI: 10.1016/S1499-3872(17)60069-9.
    [33]
    ZHANG T, LIU Y, HU Y, et al. Association of donor and recipient SUMO4 rs237025 genetic variant with new-onset diabetes mellitus after liver transplantation in a Chinese population[J]. Gene, 2017, 627:428-433. DOI: 10.1016/j.gene.2017.06.060.
    [34]
    GILLIS KA, PATEL RK, JARDINE AG. Cardiovascular complications after transplantation: treatment options in solid organ recipients[J]. Transplant Rev (Orlando), 2014, 28(2):47-55. DOI: 10.1016/j.trre.2013.12.001.
    [35]
    KATO T, GAYNOR JJ, YOSHIDA H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year[J]. Transplantation, 2007, 84(7):829-835. doi: 10.1097/01.tp.0000282914.20578.7b
    [36]
    KIM YK, LEE KW, KIM SH, et al. Early steroid withdrawal regimen prevents new-onset diabetes mellitus in old-age recipients after living donor liver transplantation[J]. World J Surg, 2012, 36(10):2443-2448. DOI: 10.1007/s00268-012-1661-6.
    [37]
    LORHO R, HARDWIGSEN J, DUMORTIER J, et al. Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study[J]. Clin Res Hepatol Gastroenterol, 2011, 35(6/7):482-488. DOI: 10.1016/j.clinre.2011.03.008.
    [38]
    HERRERO JI, QUIROGA J, SANGRO B, et al. Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus[J]. Transplant Proc, 2003, 35(5):1877-1879. doi: 10.1016/S0041-1345(03)00644-4
    [39]
    American Diabetes Association. Standards of medical care in diabetes—2014[J]. Diabetes Care, 2014, 37 (Suppl 1): S14-S80. http://pubmed.cn/24357209
    [40]
    JENSSEN T, HARTMANN A. Prevention and management of transplant-associated diabetes[J]. Expert Opin Pharmacother, 2011, 12(17):2641-2655. DOI: 10.1517/14656566.2011.628936.
    [41]
    中华医学会器官移植学分会.中国移植后糖尿病诊疗技术规范(2019版)[J].器官移植, 2019, 10(1):1-9. DOI: 10.3969/j.issn.1674-7445.2019.01.001.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specification for diagnosis and treatment of post transplantation diabetes mellitus in China[J]. Organ Transplant, 2019, 10(1):1-9. DOI: 10.3969/j.issn.1674-7445.2019.01.001.
    [42]
    NEAL DA, BROWN MJ, WILKINSON IB, et al. Mechanisms of hypertension after liver transplantation[J]. Transplantation, 2005, 79(8):935-940. doi: 10.1097/01.TP.0000158738.00927.65
    [43]
    FUJINAGA K, USUI M, YAMAMOTO N, et al. Hypertension and hepatitis C virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy[J]. Transplant Proc, 2014, 46(3):804-810. DOI: 10.1016/j.transproceed.2013.11.103.
    [44]
    TONG MS, CHAI HT, LIU WH, et al. Prevalence of hypertension after living-donor liver transplantation: a prospective study[J]. Transplant Proc, 2015, 47(2):445-450. DOI: 10.1016/j.transproceed.2014.10.050.
    [45]
    中华医学会器官移植学分会.中国实体器官移植术后高血压诊疗规范(2019版)[J].器官移植, 2019, 10(2):112-121. DOI: 10.3969/j.issn.1674-7445.2019.02.002.

    Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for hypertension after solid organ transplantation in China[J]. Organ Transplant, 2019, 10(2):112-121. DOI: 10.3969/j.issn.1674-7445.2019.02.002.
    [46]
    THOEFNER LB, ROSTVED AA, POMMERGAARD HC, et al. Risk factors for metabolic syndrome after liver transplantation: a systematic review and Meta-analysis[J]. Transplant Rev (Orlando), 2018, 32(1):69-77. DOI: 10.1016/j.trre.2017.03.004.
    [47]
    GARCÍA-PAJARES F, PEÑAS-HERRERO I, SÁNCHEZ-OCAÑA R, et al. Metabolic syndrome after liver transplantation: five-year prevalence and risk factors[J]. Transplant Proc, 2016, 48(9):3010-3012. DOI: 10.1016/j.transproceed.2016.07.038.
    [48]
    ANASTÁCIO LR, RIBEIRO HDE S, FERREIRA LG, et al. Incidence and risk factors for diabetes, hypertension and obesity after liver transplantation[J]. Nutr Hosp, 2013, 28(3):643-648. DOI: 10.3305/nh.2013.28.3.6193.
    [49]
    RABKIN JM, ROSEN HR, CORLESS CL, et al. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients[J]. Transplant Proc, 2002, 34(5):1557-1558. doi: 10.1016/S0041-1345(02)03020-8
    [50]
    GUCKELBERGER O. Long-term medical comorbidities and their management: hypertension/cardiovascular disease[J]. Liver Transpl, 2009, 15 (Suppl 2):S75-S78. DOI: 10.1002/lt.21903.
    [51]
    D'AVOLA D, CUERVAS-MONS V, MARTÍ J, et al. Cardiovascular morbidity and mortality after liver transplantation: the protective role of mycophenolate mofetil[J]. Liver Transpl, 2017, 23(4):498-509. DOI: 10.1002/lt.24738.
    [52]
    GONWA T, MENDEZ R, YANG HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months[J]. Transplantation, 2003, 75(8):1213-1220. doi: 10.1097/01.TP.0000062837.99400.60
    [53]
    WEI Q, GAO F, ZHUANG R, et al. A national report from China Liver Transplant Registry: steroid avoidance after liver transplantation for hepatocellular carcinoma[J]. Chin J Cancer Res, 2017, 29(5):426-437. DOI: 10.21147/j.issn.1000-9604.2017.05.07.
    [54]
    BARNARD A, KONYN P, SAAB S. Medical management of metabolic complications of liver transplant recipients[J]. Gastroenterol Hepatol (N Y), 2016, 12(10):601-608. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_3498400
    [55]
    SOHN AJ, JEON H, AHN J. Primary care of the liver transplant recipient[J]. Prim Care, 2011, 38(3):499-514, ix. DOI: 10.1016/j.pop.2011.05.006.
    [56]
    WARDEN BA, DUELL PB. Management of dyslipidemia in adult solid organ transplant recipients[J]. J Clin Lipidol, 2019, 13(2):231-245. DOI: 10.1016/j.jacl.2019.01.011.
    [57]
    ORLANDO G, BAIOCCHI L, CARDILLO A, et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension[J]. Liver Transpl, 2007, 13(1):46-54. doi: 10.1002/lt.20926
    [58]
    沈卫峰.难治性心血管系统疾病[M].上海:上海科学技术出版社, 2007.
    [59]
    中华医学会器官移植学分会.中国肾移植术后高尿酸血症诊疗技术规范(2019版)[J].器官移植, 2019, 10(1):10- 15. DOI: 10.3969/j.issn.1674-7445.2019.01.002.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specification for diagnosis and treatment of hyperuricemia after renal transplantation in China (2019 edition) [J]. Organ Transplant, 2019, 10(1):10-15. DOI: 10.3969/j.issn.1674-7445.2019.01.002.
    [60]
    LAINE J, HOLMBERG C. Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children[J]. Nephron, 1996, 74(2):318-323. doi: 10.1159/000189328
    [61]
    TUMGOR G, ARIKAN C, KILIC M, et al. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children[J]. Pediatr Transplant, 2006, 10(6):665-668. doi: 10.1111/j.1399-3046.2006.00556.x
    [62]
    MALHEIRO J, ALMEIDA M, FONSECA I, et al. Hyperuricemia in adult renal allograft recipients: prevalence and predictors[J]. Transplant Proc, 2012, 44(8):2369-2372. DOI: 10.1016/j.transproceed.2012.07.033.
    [63]
    KAYNAR K, ERSOZ S, ALIYAZICIOGLU R, et al. Is there any way to protect from tacrolimus-induced renal and pancreas injury? [J]. Clin Transplant, 2012, 26(5):722-728. DOI: 10.1111/j.1399-0012.2012.01603.x.
    [64]
    KANBAY M, AKCAY A, HUDDAM B, et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients[J]. Transplant Proc, 2005, 37(7):3119-3120. doi: 10.1016/j.transproceed.2005.08.042
    [65]
    中国医师协会肾脏内科医师分会.中国肾脏疾病高尿酸血症诊治的实践指南(2017版)[J].中华医学杂志, 2017, 97(25):1927-1936.DOI:10.3760/cma.j.issn. 0376-2491. 2017.25.003.

    Branch of Nephrology Physician of Chinese Medical Doctor Association. Practical guideline on the diagnosis and treatment of hyperuricemia in renal diseases in China (2017 edition) [J]. Nat Med J China, 2017, 97(25):1927-1936. DOI: 10.3760/cma.j.issn.0376-2491.2017.25.003.
    [66]
    MORENO PLANAS JM, CUERVAS-MONS MARTINEZ V, RUBIO GONZALEZ E, et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation[J]. Am J Transplant, 2004, 4(10):1650-1655. doi: 10.1111/j.1600-6143.2004.00556.x
    [67]
    KLINTMALM GB, NASHAN B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence[J]. J Transplant, 2014:845438. DOI: 10.1155/2014/845438.
    [68]
    SOFUE T, INUI M, HARA T, et al. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients[J]. Drug Des Devel Ther, 2014, 8:245-253. DOI: 10.2147/DDDT.S56597.
    [69]
    BECKMANN S, DENHAERYNCK K, STAMPF S, et al. New-onset obesity after liver transplantation-outcomes and risk factors: the Swiss Transplant Cohort Study[J]. Transpl Int, 2018, 31(11):1254-1267. DOI: 10.1111/tri.13308.
    [70]
    RICHARDS J, GUNSON B, JOHNSON J, et al. Weight gain and obesity after liver transplantation[J]. Transpl Int, 2005, 18(4):461-466. doi: 10.1111/j.1432-2277.2004.00067.x
    [71]
    SAAB S, LALEZARI D, PRUTHI P, et al. The impact of obesity on patient survival in liver transplant recipients: a Meta-analysis[J]. Liver Int, 2015, 35(1):164-170. DOI: 10.1111/liv.12431.
    [72]
    SPENGLER EK, O'LEARY JG, TE HS, et al. Liver transplantation in the obese cirrhotic patient[J]. Transplantation, 2017, 101(10):2288-2296. DOI: 10.1097/TP.0000000000001794.
    [73]
    BRAY GA, FRüHBECK G, RYAN DH, et al. Management of obesity[J]. Lancet, 2016, 387(10031):1947-1956. DOI: 10.1016/S0140-6736(16)00271-3.
    [74]
    LIM LG, CHENG CL, WEE A, et al. Prevalence and clinical associations of posttransplant fatty liver disease[J]. Liver Int, 2007, 27(1):76-80. doi: 10.1111-j.1478-3231.2006.01396.x/
    [75]
    EVERHART JE, LOMBARDERO M, LAKE JR, et al. Weight change and obesity after liver transplantation: incidence and risk factors[J]. Liver Transpl Surg, 1998, 4(4):285-296. doi: 10.1002/lt.500040402
    [76]
    CHARLTON M, RINELLA M, PATEL D, et al. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study[J]. Transplantation, 2017, 101(12):2873-2882. DOI: 10.1097/TP.0000000000001913.
    [77]
    APOVIAN CM, ARONNE LJ, BESSESEN DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2015, 100(2):342-362. DOI: 10.1210/jc.2014-3415.
    [78]
    KOPELMAN PG. Obesity as a medical problem[J]. Nature, 2000, 404(6778):635-643. doi: 10.1038/35007508
    [79]
    LAZZATI A, IANNELLI A, SCHNECK AS, et al. Bariatric surgery and liver transplantation: a systematic review a new frontier for bariatric surgery[J]. Obes Surg, 2015, 25(1):134-142. DOI: 10.1007/s11695-014-1430-8.
    [80]
    AYLOO S, ARMSTRONG J, HURTON S, et al. Obesity and liver transplantation[J]. World J Transplant, 2015, 5(3):95-101. DOI: 10.5500/wjt.v5.i3.95.
    [81]
    中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志, 2013, 29(11):913-920.DOI: 10.3760/cma.j.issn.1000-6699.2013.11.001.

    Branch of Endocrinology of Chinese Medical Association. Chinese expert consensus on the treatment of hyperuricemia and gout [J]. Chin J Endocrinol Metabol, 2013, 29(11):913-920.DOI: 10.3760/cma.j.issn.1000-6699.2013.11.001.
    [82]
    中华医学会内分泌学分会.中国2型糖尿病合并肥胖综合管理专家共识[J].中华内分泌代谢杂志, 2016, 32(8): 623-627.DOI: 10.3760/cma.j.issn.1000-6699.2016.08.001.

    Branch of Endocrinology of Chinese Medical Association. Experts consensus on comprehensive management of type 2 diabetes mellitus complicated with obesity in China [J]. Chin J Endocrinol Metabol, 2016, 32(8):623-627. DOI: 10.3760/cma.j.issn.1000-6699.2016.08.001.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (531) PDF downloads(90) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return